United Therapeutics' regenerative medicine partnership with 3D Systems, Inc., focused on the manufacture of human lungs, reached a new printing milestone in the second quarter of 2025. This achievement signifies continued progress in the development of bio-artificial organs.
This milestone resulted in a $2 million award for 3D Systems in the second quarter, indicating a successful advancement in the collaborative research and development efforts. The partnership aims to address the critical shortage of transplantable organs through innovative bioprinting technologies.
The development of complex lung scaffolds capable of gas exchange in preclinical models is a key component of United Therapeutics' ULung program. This progress reinforces the company's position at the forefront of bio-artificial organ development and its long-term vision for transforming healthcare.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.